Skip to main content
About PLI PLUS
- Answer Books
- Course Handbooks
< Back To Results
1 in 1 results
Developments in Pharmaceutical and Biotech Patent Law 2019
David K. Barr
PLI Item #:
CHB Spine #:
This version is not current.
Click here for the most recent version.
Add To Bookshelf
Table of Contents
Table of Contents
Chapter 1. Excerpt from Ch. 5: Patentability, Practising Law Institute, Pharmaceutical and Biotech Patent Law § 5:8 (March 2019)
Chapter 2. Blocking Patents and the Proper Role of Objective Indicia in Determining Nonobviousness
Chapter 3. Post-TC Heartland Venue Issues in Hatch-Waxman Cases and the Printed Matter Doctrine
Chapter 4. Patent Due Diligence in Pharmaceutical and Biotech Patent Transactions
Chapter 5. Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015)
Chapter 6. Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited, 887 F.3d 1117 (Fed. Cir. 2018)
Chapter 7. Berkheimer v. HP Inc., 890 F.3d 1369 (Fed. Cir. 2018)
Chapter 8. Athena Diagnostics, Inc. v. Mayo Collaborative Services, LLC, 2019 WL 2847219 (Fed. Cir. July 3, 2019)
Chapter 9. Rapid Litigation Management Ltd. v. CellzDirect, Inc., 827 F.3d 1042 (Fed. Cir. 2016)
Chapter 10. 2019 Revised Patent Subject Matter Eligibility Guidance, Federal Register, Vol. 84, No. 4 (January 7, 2019)
Chapter 11. U.S. Senators Chris Coons (D-Del.) and Thom Tillis (R-N.C.), and Representatives Doug Collins (R-Ga.), Hank Johnson (D-Ga.) and Steve Stivers (R-Ohio), Section 101 Patent Reform Framework and Draft Bill (April–May 2019)
Chapter 12. Post-Grant Proceedings in Life Sciences: Strategic Patent Considerations
Chapter 13. Supplemental Materials for Post-Grant Proceedings in Life Sciences: Strategic Patent Considerations
Chapter 14. Sanjay K. Murthy, Michael T. Sikora and Christopher J. Hall, Ethical Issues Confronting Life Sciences Patent Lawyers
All Contents Copyright © 1996-2020 Practising Law Institute.
PLI Librarian Blog
PLI PLUS app
Continuing Legal Education since 1933.